News | Drug-Eluting Balloons | September 14, 2023

BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months

First dedicated registry to investigate DCB performance in isolated popliteal artery lesions shows Passeo-18 Lux DCB as beneficial treatment for challenging anatomical segment 

First dedicated registry to investigate DCB performance in isolated popliteal artery lesions shows Passeo-18 Lux DCB as beneficial treatment for challenging anatomical segment

September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark.1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. 

BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the Netherlands, and Luxembourg with Rutherford 2-5 disease and at least two centimeters of healthy vessel segment between lesions in the popliteal artery and lesions in the distal superficial femoral artery. All patients were treated with the Passeo-18 Lux DCB. The bail-out stenting rate was 14%. 

At 24 months: 

  • Freedom from clinically driven target lesion revascularization (CD-TLR)2 was 81.6% 
  • Freedom from major target limb amputation was 98.0% 
  • Freedom from all-cause of death was 89.4% 
  • Significant improvement of Rutherford classification was observed for 88.1% of the patients 

 

"We face a scarcity of data evaluating endovascular therapy for isolated popliteal artery lesions, known as a difficult vessel bed to treat as we don’t want to leave anything behind," said Principal Investigator Prof. Frank Vermassen, Chief of Vascular and Thoracic Surgery at UZ Ghent in Ghent, Belgium. "It is encouraging to see that we can safely and effectively treat these lesions with a DCB-only approach." 

"BIOTRONIK is proud to be a leader in research of paclitaxel-coated balloons, striving to study device performance in the most challenging anatomy and patient characteristics," said Stuart Perks, Vice President of Marketing, Vascular Intervention at BIOTRONIK. "We repeatedly see the safety and effectiveness of Passeo-18 Lux DCB demonstrated in a diverse range of clinical presentations." 

For more information: www.biotronik.com 

 

References:    

1 Vermassen F. A prospective, international, multi-centre, post-market all-comers registry to assess the clinical performance of the Passeo-18 Lux DCB in isolated popliteal arteries – BIOLUX P-III BENELUX. Presented at: CIRSE 2023; September 9-13, 2023; Copenhagen, Denmark. 

2 CD-TLR is defined as any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.

Passeo and Lux are trademarks or registered trademarks of the BIOTRONIK Group of Companies. 

Passeo-18 Lux paclitaxel-releasing PTA balloon catheter is not available for sale or use in the United States.   

 

Related Content: 

BIOPACT RCT Subgroup Analyses Show Consistently Great Results for Passeo-18 Lux Drug-Coated Balloon 

One-Year BIOPACT Randomized Controlled Trial (RCT) Results Demonstrate Excellent Results for Low-Profile Passeo-18 Lux DCB  

New Data at LINC 2022 Confirm Passeo-18 Lux Drug-Coated Balloon is a Safe and Effective Treatment in Challenging Patient Groups


Related Content

News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
News | Stents

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
News | Stents

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
News | Stents

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
News | Stents

April 6, 2022 – Narrowed arteries can restrict blood flow to the heart. One treatment is inserting a stent — a small ...

Home April 06, 2022
Home
Subscribe Now